Co-Immune banner
program logo

Co-Immune

13
Projects
21
Needs
85
Members

An open science initiative to collectively address the contemporary challenges of vaccination.

program logo

Co-Immune

Co-Immune

An open science initiative to collectively address the contemporary challenges of vaccination


Co-Immune is a collaborative and open research program elaborated and implemented by Just One Giant Lab (JOGL) which aims to tackle contemporary challenges related to vaccination by enhancing collective intelligence, using digital tools and open data. This program offers challenges, mentorship and an independent peer-reviewing system. It is open to anyone who wishes to contribute to building knowledge and innovative solutions around vaccination coverage in a collaborative and open science framework. Hence, ensuring an unlimited and open access and use of all produced material to accelerate the sharing of impactful initiatives.


Vaccination is one of the most efficient health interventions available to us (1). However, vaccine-preventable diseases are now on the rise in France and around the world (2), alarming the World Health Organization (WHO), regional and local stakeholders (1). In France, Agnes Buzyn, Minister of Solidarity and Health, has made this issue a priority (4). Co-Immune joins these ongoing global dynamic and efforts by proposing an inclusive and collaborative approach to increase the number and diversity of contributors and foster the emergence of open solutions.



___

(1) Organisation mondiale de la Santé. Plan d’action mondial pour les vaccins 2011-2020. Organisation mondiale de la Santé; 2013. 77 p.

(2) Cour des comptes. La politique vaccinale : un enjeu de santé publique, un effort à conforter. In: Rapport public annuel 2018. 2018. p. 38.

(4) Agnès Buzyn. Communiqué de presse du 18 avril 2019, Semaine Européenne de la Vaccination du 24 au 30 avril 2019. Une campagne nationale inédite et des premiers résultats positifs de l'obligation vaccinale.




GOALS

Contribute to improving vaccination coverage in France and around the world






HOW TO PARTICIPATE


To participate to the program, participate to one of the challenges launched by Co-Immune. Their themes, questions, rules of participation and criteria of evaluation, are all describded in the challenges' pages.


To participate to the challenges, it's simple: create a project or join and contribute to already created projects to try and find solutions to the challenges. 

 

You can also support the program or its projects by becoming an enabler. Contact JOGL directly through this link.




 TIMELINE





Committee for Ethics, Science and Impact (CESI)


Role


Representing all stakeholders and the major disciplines involved with vaccination, an honorary and independent Committee for Ethics, Science and Impact (CESI) ensures compliance with legal and regulatory provisions, in terms of ethics and scientific integrity.

 

The CESI is also in charge of validating the rules of participation as well as co-elaborating the criteria for evaluating the scientific quality, relevance and impact of the projects that will be used by independent reviewers. At the end of the program, the Committee will rely on reviewers' evaluations to reward the best collective productions. 


Members



- Gilles Babinet, entrepreneur, vice-president of the Conseil national du numérique, digital champion of France at the European Union.


- Jérôme Béranger, lecturer and writer, researcher in digital ethics at Inserm, co-founder and CSO of ADEL (Algorithm Data Ethics Label).


- Anshu Bhardwaj, one of the founding PIs of Open Source Drug Discovery in India, researcher at the Center for Research and Interdisciplinarity in Paris, and researcher and assistant professor at the CSIR-Institute of Microbial Technology, India.


- Liem Binh Luong Nguyen, infectiologist, researcher at the Pasteur Institute and Vaccinology Centre at Cochin Hospital.


- Mélanie Heard, researcher and teacher at the Center for Research and Interdisciplinarity, previously advisor to the French National Authority for Health (HAS) and the French Ministry of Health and Solidarity.


- Ariel Lindner, Research Director at Inserm and co-founder of the Center for Research and Interdisciplinarity (CRI).


- Juliette Puret, health economist focusing on sustainable access to vaccines for resource-limited countries, Senior program manager at GAVI, she has also worked for Doctors without Borders, the World Health Organization, and the World Bank


- Olivier Rozaire, pharmacist. President of the Regional Union of Health Professionals (URPS) pharmacists of Auvergne-Rhône-Alpes and president of the Syndicat USPO.


If you are interested in joining the CESI, please contact us on hello@jogl.io. We would love to have all the disciplines involved in vaccination represented.


ANY QUESTIONS?

Wish to participate? Have questions or considerations? Need more precision? Don't hesitate to contact JOGL. Click on "Contact us". We are here to answer any of your questions.

Supporters

CORE ENABLER




Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.


JOGL's approach fully resonates with Sanofi's approach to e-health: open, inclusive and people-centered. That is why Sanofi is a partner of JOGL and supports the Co-Immune program.


Sanofi's support for Co-Immune, as part of its partnership with JOGL, consists of 4 components: financial support, human expertise, data collection and communication support.


Sanofi respects the strict independence of JOGL, which administers its platform and the Co-Immune page in complete autonomy. Similarly, the Committee for Ethics, Science and Impact (CESI) is independent of Sanofi and decides alone on the strategic and scientific orientations of the program and the best projects to be rewarded.




CO-ENABLERS